Teva debuts generic Perforomist
Teva’s generic Perforomist is indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease.
Teva is offering the first generic version of twice-daily Perforomist, formoterol fumarate inhalation solution 20 mcg/2 ML.
The product is indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Perforomist has a market value of more than $299 million, according to March 2021 IQVIA data.